Spots Global Cancer Trial Database for mutation
Every month we try and update this database with for mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC | NCT04405661 | NSCLC | 18 Years - 70 Years | Guangzhou Institute of Respiratory Disease | ||
| Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC | NCT01775943 | Lung Neoplasms | - | Ulsan University Hospital | ||
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | NCT03974022 | Non-Small Cell ... | Sunvozertinib | 18 Years - | Dizal Pharmaceuticals | |
| Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests | NCT03889171 | Cancer Colorectal Canc... Breast Cancer Ovarian Cancer | Behaviour | 18 Years - | University Hospital, Montpellier | |
| Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²) | NCT02448758 | Non-Small Cell ... | 18 Years - | Centre Oscar Lambret | ||
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | NCT02186821 | Tumors With Abe... | Ceritinib | 18 Years - | Novartis | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | NCT01774721 | Non-small Cell ... | Dacomitinib (PF... Gefitinib | 18 Years - 99 Years | Pfizer | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| Phenotype and Etiology of Pallister-Hall Syndrome | NCT00001404 | Malformations Multiple Abnorm... Polydactyly | - | National Institutes of Health Clinical Center (CC) | ||
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer | NCT03786575 | Breast Neoplasm... Therapeutics Mutation | Next Generation... | 18 Years - | Peking Union Medical College | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| Integrative Sequencing In Germline and Hereditary Tumours | NCT03857594 | Hereditary Canc... High-Risk Mutation Germline Mutati... | 18 Years - | University Health Network, Toronto | ||
| Utility of Primary Glioblastoma Cell Lines | NCT04180046 | Tumor Brain Tumor | - | Neuromed IRCCS | ||
| Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation | NCT05263947 | Carcinoma, Non-... Bevacizumab EGF-R Positive ... Tyrosine Kinase... | Bevacizumab and... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease | NCT02612350 | Mutation Neoplasms | ctDNA Analysis ... | 18 Years - | Pathway Genomics | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease | NCT02612350 | Mutation Neoplasms | ctDNA Analysis ... | 18 Years - | Pathway Genomics | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma | NCT02039388 | Ovarian Epithel... Carcinoma in Si... Ovarian Cancer | Lavage of the C... | 18 Years - 80 Years | Medical University of Vienna | |
| Prognostic Value of Each Codon-specific KRAS Mutation in Colorectal Cancer | NCT05657210 | Colorectal Canc... | Mutation | - | Seoul National University Bundang Hospital | |
| Mutation Detection for VRL | NCT05102994 | Vitreoretinal L... Uveitis | mutation test | 18 Years - 70 Years | Sun Yat-sen University | |
| Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma | NCT02815137 | Classical Hodgk... | Digital Polymer... | 18 Years - | Centre Henri Becquerel | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA) | NCT02034656 | Chronic Myeloid... | 18 Years - | Seoul St. Mary's Hospital | ||
| Molecular Mechanisms and Diagnosis of Mastocytosis | NCT00336076 | Mastocytosis | Collection of b... | - | University of Michigan | |
| Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²) | NCT02448758 | Non-Small Cell ... | 18 Years - | Centre Oscar Lambret | ||
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | NCT01831726 | Tumor Pathway A... | Dovitinib (TKI2... | 18 Years - 100 Years | Novartis | |
| The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | NCT01942993 | Melanoma | Vemurafenib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients | NCT05901025 | Breast Cancer | - | Shanghai Jiao Tong University School of Medicine | ||
| Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer | NCT03786575 | Breast Neoplasm... Therapeutics Mutation | Next Generation... | 18 Years - | Peking Union Medical College | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| Phenotype and Etiology of Pallister-Hall Syndrome | NCT00001404 | Malformations Multiple Abnorm... Polydactyly | - | National Institutes of Health Clinical Center (CC) | ||
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | NCT05768178 | Solid Tumor Haematological ... Melanoma Thyroid Cancer,... Ovarian Neoplas... Colorectal Neop... Laryngeal Neopl... Carcinoma, Non-... Glioma Multiple Myelom... Erdheim-Chester... Thyroid Carcino... | Vemurafenib Cobimetinib | 18 Years - | Cancer Research UK | |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | NCT03974022 | Non-Small Cell ... | Sunvozertinib | 18 Years - | Dizal Pharmaceuticals | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor | NCT00001148 | Astrocytoma Glioblastoma Glioma | - | National Institutes of Health Clinical Center (CC) | ||
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | NCT01219699 | Advanced Solid ... Estrogen Recept... | BYL719 Fulvestrant | 18 Years - | Novartis | |
| Molecular Profiling in Prostate Cancer | NCT04983628 | Prostate Cancer... Prostate Cancer... Germline BRCA1 ... Germline BRCA2 ... Mutation | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma | NCT06178809 | Hepatocellular ... | 18 Years - 80 Years | Singlera Genomics Inc. | ||
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | NCT01219699 | Advanced Solid ... Estrogen Recept... | BYL719 Fulvestrant | 18 Years - | Novartis | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| Gene Mutations in Non-Small Cell Lung Cancer Cells | NCT00977509 | Carcinoma, Non-... | 20 Years - | National Taiwan University Hospital | ||
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | NCT02980536 | Nonsmall Cell L... Adenocarcinoma | 18 Years - | Berry Genomics Co., Ltd. | ||
| BGJ398 for Patients With Tumors With FGFR Genetic Alterations | NCT02160041 | Solid Tumor Hematologic Mal... | BGJ398 | 18 Years - | Novartis | |
| Molecular Markers in Thyroid Cancer | NCT00598364 | Thyroid Cancer | 1 Year - | OHSU Knight Cancer Institute | ||
| Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | NCT02355431 | Solid Tumors an... NSCLC (Non-smal... | Itacitinib erlotinib placebo | 18 Years - | Incyte Corporation | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | NCT03925350 | Metastatic Mela... | Niraparib | 18 Years - | California Pacific Medical Center Research Institute | |
| Prognostic Value of Each Codon-specific KRAS Mutation in Colorectal Cancer | NCT05657210 | Colorectal Canc... | Mutation | - | Seoul National University Bundang Hospital | |
| Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC | NCT01775943 | Lung Neoplasms | - | Ulsan University Hospital | ||
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | NCT03925350 | Metastatic Mela... | Niraparib | 18 Years - | California Pacific Medical Center Research Institute | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | NCT03974022 | Non-Small Cell ... | Sunvozertinib | 18 Years - | Dizal Pharmaceuticals | |
| Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients | NCT05901025 | Breast Cancer | - | Shanghai Jiao Tong University School of Medicine | ||
| Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities | NCT05311709 | Lung Cancer NSCLC, Stage II... NSCLC Stage IV Lung Cancer Sta... Mutation Cancer Cancer, Lung | sotorasib | 18 Years - | Vestre Viken Hospital Trust | |
| Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions | NCT03160274 | Pheochromocytom... Paraganglioma Inherited Cance... Associated Cond... Kidney Neoplasm... Bone Cancer Thyroid Neoplas... Other Cancer | Genetic screeni... | - | The University of Texas Health Science Center at San Antonio | |
| Phenotype and Etiology of Pallister-Hall Syndrome | NCT00001404 | Malformations Multiple Abnorm... Polydactyly | - | National Institutes of Health Clinical Center (CC) | ||
| Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | NCT05886920 | Advanced Solid ... | D3S-002 | 18 Years - | D3 Bio (Wuxi) Co., Ltd | |
| Molecular Markers in Cancers and Precancers (MOCA) | NCT05257707 | Cancer Precancerous Le... Healthy | Molecular biolo... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | NCT05275673 | Non-Small Cell ... Squamous Non-sm... Squamous Non-Sm... NFE2L2 Gene Mut... | sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | NCT05410145 | KRAS P.G12C | D3S-001 Pembrolizumab Cisplatin Carboplatin Pemetrexed Cetuximab | 18 Years - | D3 Bio (Wuxi) Co., Ltd | |
| cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | NCT02980536 | Nonsmall Cell L... Adenocarcinoma | 18 Years - | Berry Genomics Co., Ltd. | ||
| Liquid Biopsy Evaluation and Repository Development at Princess Margaret | NCT03702309 | Cancer Breast Cancer Lung Cancer Colon Cancer Ovarian Cancer Melanoma Lymphoma Leukemia Mutation Lynch Syndrome Cowden Syndrome BRCA1 Mutation BRCA2 Mutation Uterine Cancer Myeloma Kidney Cancer Head and Neck C... Meningioma | 18 Years - | University Health Network, Toronto | ||
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
